At-Home taVNS for Neurorehabilitation in Parkinson's Disease
Summary
NIH registered a new clinical trial (NCT07536022) evaluating at-home transcutaneous auricular vagus nerve stimulation (taVNS) for neurorehabilitation in approximately 40 adults with Parkinson's Disease. The 8-week study will assess feasibility, tolerability, and preliminary efficacy of self-administered daily 1-hour taVNS sessions using a threshold-based individual dosing protocol. Secondary objectives include measuring changes in motor and non-motor symptoms and examining neural network connectivity via MRI.
What changed
NIH registered a new clinical trial on ClinicalTrials.gov studying at-home transcutaneous auricular vagus nerve stimulation (taVNS) as a potential neurorehabilitation treatment for Parkinson's Disease. The single-arm feasibility study will enroll approximately 40 adult participants who will self-administer 1-hour daily taVNS sessions for 8 weeks following threshold measurement and initial supervised training with vital monitoring.
For clinical investigators and researchers focused on neuromodulation or movement disorders, this trial represents a novel application of non-invasive vagus nerve stimulation for neurodegenerative disease. Medical device manufacturers developing or marketing taVNS or similar peripheral nerve stimulation devices should monitor enrollment outcomes and preliminary efficacy data, as positive results could support expanded clinical development or regulatory submissions. Patients with Parkinson's Disease may wish to discuss trial participation eligibility with their neurologists.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
At-home taVNS for Neurorehabilitation in Parkinson's Disease
N/A NCT07536022 Kind: NA Apr 17, 2026
Abstract
The goal of this clinical trial is to learn if taVNS works to treat symptoms of Parkinson's Disease in adults. It will also learn about the feasibility and preliminary efficacy of taVNS administered at home by the participant.
The main questions it aims to answer are:
- Is at-home taVNS feasible and effective for treating symptoms of Parkinson's Disease? How often are participants completing the stimulation protocol? What are the side effects of stimulation experienced by participants? How do participants rate the experience of taVNS sessions at home? How do participants' scores on assessments and questionnaires change with taVNS treatments?
- How does taVNS impact connections between neural networks in the brain of patients with Parkinson's Disease at rest?
Participants will:
- Have a baseline MRI scan to take images of their brain.
- Complete a series of assessments and questionnaires to evaluate their Parkinson's Disease motor symptoms, cognitive and neuropsychiatric symptoms, and other non-motor symptoms.
- Have an initial taVNS session where their threshold to perceive the stimulation will be measured. This value will be used to stimulate each participant at a specific dose relative to their individual perception of stimulation.
- Be trained on how to use the taVNS device and system and have one 1-hour taVNS session where their vitals will be monitored.
- Self-administer 1-hour daily taVNS sessions for 8 weeks at-home, complete tolerability questionnaires, and w...
Conditions: Parkinson's Disease
Interventions: transcutaneous auricular nerve stimulation
Named provisions
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.